Advertisement
BMY or GSK or NVS
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. GSK plc (GSK) vs. Novartis AG (NVS) Stock Comparison
Key Takeaways
- Bristol-Myers Squibb (BMY) has delivered recent positive clinical data on Sotyktu in psoriatic arthritis alongside a reaffirmed dividend, supporting sentiment in recent market activity.
- GSK plc (GSK) received an analyst upgrade to Buy from Berenberg in September 2026, citing pipeline momentum and business development progress.
- Novartis AG (NVS) faced trial setbacks in ALS and other programs in mid-September 2026, contributing to volatility despite earlier multiple sclerosis data wins.
- All three companies operate in the pharmaceuticals sector with exposure to patent cycles, pipeline catalysts, and dividend yields that appeal to income-focused investors.
- Relative performance shows Bristol-Myers Squibb (BMY) with stronger year-to-date gains compared to peers amid broader sector dynamics.
- Valuation metrics, including forward price-to-earnings ratios, position Bristol-Myers Squibb (BMY) as relatively attractive versus historical averages.
Introduction
Investors and traders often compare pharmaceutical stocks such as Bristol-Myers Squibb (BMY), GSK plc (GSK), and Novartis AG (NVS) to assess relative positioning within the healthcare sector. These companies share exposure to innovative drug development, regulatory approvals, and patent expirations that influence revenue trajectories. The comparison appeals to those evaluating dividend sustainability, pipeline strength, and sensitivity to broader market sentiment shifts. Recent weeks have highlighted differing catalysts, including clinical readouts and analyst commentary, that shape short-term price behavior across the group. This analysis provides a factual overview of business contexts and observable performance factors without forward projections.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) develops and commercializes therapies in oncology, immunology, cardiovascular, and neuroscience areas. In recent market activity, the stock has traded near $63 amid a 52-week range of approximately $42.52 to $68.64. Year-to-date returns reached about 21 percent through mid-September 2026, outpacing some peers. Key influences include positive two-year data for Sotyktu in psoriatic arthritis announced in September and a quarterly dividend declaration. Earlier second-quarter results showed revenue growth and raised full-year guidance, contributing to sustained momentum. Pipeline updates on CAR-T candidates and manufacturing investments have also featured in recent developments, supporting sentiment around long-term portfolio diversification.
GSK Overview and Recent Performance
GSK plc (GSK) focuses on specialty medicines, vaccines, and general medicines with emphasis on respiratory, oncology, and HIV portfolios. The stock has responded to second-quarter core results that demonstrated sales growth of 5 percent at constant exchange rates and reaffirmed 2026 guidance for turnover expansion of 3 to 5 percent. In September 2026, Berenberg upgraded the shares to Buy with an increased target price, highlighting business development activity and late-stage pipeline acceleration plans, including multiple Phase III starts. Restructuring initiatives aimed at cost savings to fund research have been noted as supporting operational efficiency. Recent performance reflects these factors alongside ongoing shareholder returns through dividends and completed buyback programs.
NVS Overview and Recent Performance
Novartis AG (NVS) maintains a diversified portfolio spanning oncology, cardiology, neuroscience, and immunology. Shares traded near $140 in mid-September 2026 within a 52-week range of roughly $121.57 to $170.46. Recent developments include a Phase 3 win for remibrutinib in relapsing multiple sclerosis reported in early September, offset by mid-month halts in ALS development and failures in other late-stage studies for del-desiran and pelacarsen. These mixed outcomes contributed to short-term price pressure and prompted shareholder commentary on governance. Positive European opinions for Cosentyx expansions provided counterbalancing news. Broader quarterly results from earlier in the period reaffirmed low single-digit sales growth expectations for 2026.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots from hundreds available across thousands of tickers. Only those demonstrating strong suitability for prevailing market conditions earn placement in this section, reflecting varied trading styles, strategies, timeframes, and performance statistics. Available bots cover ranges of historical win rates, drawdown metrics, and return profiles tailored to different risk tolerances and asset classes. Users can explore detailed statistics on each bot’s ticker focus and backtested outcomes to identify alignments with personal objectives. Review the full selection on the Trending AI Robots page for additional insights.
Head-to-Head Comparison
Bristol-Myers Squibb (BMY), GSK plc (GSK), and Novartis AG (NVS) differ in business model emphasis, with Bristol-Myers Squibb (BMY) maintaining broad therapeutic diversification and GSK plc (GSK) prioritizing vaccines alongside specialty medicines. Novartis AG (NVS) balances established franchises with targeted pipeline bets. Recent momentum favors Bristol-Myers Squibb (BMY) through consistent clinical updates, while GSK plc (GSK) benefits from analyst upgrades and GSK plc (GSK)’s restructuring clarity. Novartis AG (NVS) exhibits greater short-term volatility tied to trial outcomes. Risk factors include patent cliffs across all three, with sector exposure amplifying sensitivity to regulatory and pricing environments. Valuation metrics show Bristol-Myers Squibb (BMY) trading at lower forward multiples relative to peers, potentially appealing to value-oriented participants, whereas Novartis AG (NVS) commands premiums amid larger market capitalization. Market sentiment reflects these contrasts through differential price reactions to news flow.
Tickeron AI Verdict
Based on observable factors such as trend consistency in recent clinical data releases, valuation stability, and relative positioning versus sector peers, Tickeron’s AI would likely assign higher probabilistic weight to Bristol-Myers Squibb (BMY) in the current environment. Positive pipeline readouts and dividend support provide measurable catalysts that align with patterns of sustained interest. GSK plc (GSK) follows closely due to analyst momentum, while Novartis AG (NVS) shows more variable signals from mixed trial results. This assessment remains probabilistic and derived from available performance indicators rather than guarantees of future outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsBMY | GSK | NVS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 59 | 81 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 42 Fair valued | 5 Undervalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 81 | 51 | 10 | |
SMR RATING 1..100 | 22 | 34 | 33 | |
PRICE GROWTH RATING 1..100 | 46 | 60 | 53 | |
P/E GROWTH RATING 1..100 | 65 | 56 | 21 | |
SEASONALITY SCORE 1..100 | 75 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (4) in the Pharmaceuticals Major industry is in the same range as GSK (5) and is somewhat better than the same rating for BMY (42). This means that NVS's stock grew similarly to GSK’s and somewhat faster than BMY’s over the last 12 months.
NVS's Profit vs Risk Rating (10) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (51) and is significantly better than the same rating for BMY (81). This means that NVS's stock grew somewhat faster than GSK’s and significantly faster than BMY’s over the last 12 months.
BMY's SMR Rating (22) in the Pharmaceuticals Major industry is in the same range as NVS (33) and is in the same range as GSK (34). This means that BMY's stock grew similarly to NVS’s and similarly to GSK’s over the last 12 months.
BMY's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as NVS (53) and is in the same range as GSK (60). This means that BMY's stock grew similarly to NVS’s and similarly to GSK’s over the last 12 months.
NVS's P/E Growth Rating (21) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (56) and is somewhat better than the same rating for BMY (65). This means that NVS's stock grew somewhat faster than GSK’s and somewhat faster than BMY’s over the last 12 months.
| BMY | GSK | NVS | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 50% | 1 day ago 64% | 1 day ago 58% |
| Stochastic ODDS (%) | 1 day ago 59% | 1 day ago 63% | 1 day ago 57% |
| Momentum ODDS (%) | 4 days ago 49% | 1 day ago 48% | 1 day ago 51% |
| MACD ODDS (%) | N/A | 1 day ago 48% | 1 day ago 57% |
| TrendWeek ODDS (%) | 1 day ago 54% | 1 day ago 55% | 1 day ago 54% |
| TrendMonth ODDS (%) | 1 day ago 55% | 1 day ago 53% | 1 day ago 51% |
| Advances ODDS (%) | 4 days ago 56% | 4 days ago 63% | 13 days ago 54% |
| Declines ODDS (%) | 1 day ago 53% | 1 day ago 55% | 5 days ago 45% |
| BollingerBands ODDS (%) | 1 day ago 62% | 1 day ago 63% | 1 day ago 38% |
| Aroon ODDS (%) | 1 day ago 54% | 1 day ago 46% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 1 FA rating(s) are green while GSK’s FA Score has 1 green FA rating(s), and NVS’s FA Score reflects 4 green FA rating(s).
- BMY’s FA Score: 1 green, 4 red.
- GSK’s FA Score: 1 green, 4 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 4 TA indicator(s) are bullish while GSK’s TA Score has 4 bullish TA indicator(s), and NVS’s TA Score reflects 4 bullish TA indicator(s).
- BMY’s TA Score: 4 bullish, 5 bearish.
- GSK’s TA Score: 4 bullish, 7 bearish.
- NVS’s TA Score: 4 bullish, 6 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а -3.32% price change this week, while GSK (@Pharmaceuticals: Major) price change was -1.13% , and NVS (@Pharmaceuticals: Major) price fluctuated +1.95% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.53%. For the same industry, the average monthly price growth was -5.20%, and the average quarterly price growth was +5.33%.
Reported Earning Dates
BMY is expected to report earnings on Oct 29, 2026.
GSK is expected to report earnings on Oct 28, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-2.53% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.